Moreover, studies aimed at defining a delivery strategy for siRNA in GBM tumors are currently ongoing in our laboratory, and the strategy tested may allow the assessment of therapeutic siRNAs specific to EGFR and Rictor in GBM in the near future. The gene discussed is EGFR; the disease is glioblastoma.